RIS Rx – Trademark Portfolio
Entity Type: 03
RIS Rx holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 2 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 5 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include RIS RX and PREVAIL. The owner is based in Yorba Linda, CA.
16635 Lathrop Drive
Yorba Linda, CA 92886
Showing of trademarks Trademarks
Trademark Classifications
RIS Rx's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Insurance; financial affairs; monetary affairs; real estate affairs
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Legal services; security services for the protection of property and individuals
Frequently Asked Questions
How many trademarks does RIS Rx have?
RIS Rx has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned.
What trademark classes does RIS Rx file in?
RIS Rx files trademarks across 5 Nice Classification classes. The most active classes are Class 36 (Insurance & Financial), Class 44 (Medical Services), Class 35 (Advertising & Business), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.
What are RIS Rx's most well-known trademarks?
RIS Rx's registered trademark portfolio includes well-known marks such as RIS RX and PREVAIL. These are among 2 currently registered trademarks in the portfolio.
What is RIS Rx's trademark registration success rate?
RIS Rx has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.